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ABSTRACT
Objective: Neurodegenerative disorders are group of diseased conditions in which there is loss of neuron cells occur. The main objective of this study 
to find/search out the phytochemical with the help of prediction of activity spectra of substances (PASS), those show maximum activity over the 
selected targets of the Parkinson’s disease (PD).
Methods: PASS is a valuable software which is used in this study, to predict the anti-Parkinson activity of different compounds. Canonical simplified 
molecular-input line-entry system is used for the prediction of anti-Parkinson activity which is obtained from PubChem website. The predicted 
activity also compared with marketed compound like levodopa.
Results: From the study, it was found that resveratrol was the only compound which has the activity on all the selected targets. On the other hand, 
stemazole and celastrol were found to have the least active compounds as both have the activity only on a single target.
Conclusion: In this research work, we tried to compile the information regarding the PASS predicted anti-Parkinson activity of some important 
phytoconstituents. We found that resveratrol can be a target for further investigation in the development of drug therapy for PD.
Keywords: Parkinson’s disease, Prediction of activity spectra of substances, Levodopa, Postural instability.
INTRODUCTION
Parkinson disease (PD) is the second most common, age-related chronic 
neurodegenerative disorder. Nowadays, PD is the most prevalent disease. 
Approximate 7–10 million people of the world surviving with the PD, of 
these 1 million lives in the U.S. men are at a greater risk of PD compared 
to woman. As the age increases, the incidence of PD also increases. Mostly 
the people with the age of 60 years or above are the targets of the PD. 
PD becomes the 14th leading cause of death in the U.S [1,2]. The key 
symptoms of PD are tremors, rigidity, bradykinesia, postural instability, 
cognitive dysfunction, and sleep disturbance. These symptoms appeared 
due to progressive loss of dopaminergic neurons in substantia nigra pars 
compacta of brain, which further lead to loss of dopamine (DA) [2,3]. 
Another pathological hallmark of PD is the presence of eosinophilic 
intracytoplasmic proteinaceous inclusion bodies that are mainly 
composed of fibrillar α-synuclein termed Lewy bodies and dystrophic 
neurites (Lewy neurites) presents in surviving neurons [4].
The etiology of PD is still unknown, but there are several factors such as 
environmental, genetics, age, and medication which can be responsible 
for the development of PD. The available drug therapy which includes 
levodopa and carbidopa provide only symptomatic relief but able to 
cure the underline cause of the PD. These drugs also produce certain 
side effects such as nausea, vomiting, hallucination, convulsions, and 
dry mouth (Fig. 1) [1,5].
Herbal medicines have a long history of safe and efficacious 
administration as therapeutic agent or dietary supplement in different 
parts of the world. Due to the presence of various type of phytochemical 
in them, these herb possesses protective and therapeutic effect in 
various indications. Nowadays, plant chemicals are of great interest 
for the development of medicine for various diseases [6]. Development 
of new safe and effective medicine is not an easy task. Various 
phytochemicals have been reported to be effective in in vitro and in 
vivo models of PD, but no one can enter into the mainstream of drug 
development due to lack of information.
Prediction of activity spectra for substances (PASS) is a computer-based 
software, which provides the information regarding the biological 
activities on different targets of the chemical compound on the bases 
of their chemical structure. The software predicts the activity of the 
compound in two probabilities; one is probable activity (Pa) and 
another one is probable inactivity (Pi). The value of Pa and Pi varies 
from 0.000 to 1.000. If Pa > Pi for any activity, only then that activity 
can be designated to the compound. If Pa value is more than 0.7 for any 
activity, then the probability of that action is high in pharmacological 
experiment. If Pa value is more than 0.5 but <0.7 for any activity, then 
the probability of that action is less in pharmacological experiment. 
If Pa value is <0.5, then the probability of observing that activity in 
pharmacological experiment is less [7-10].
METHODS
For the evaluation of the activity using PASS, first, we select certain 
phytoconstituents which have already reported to have pharmacological 
effect in the in vivo and in vitro models of PD, and one marketed standard 
drug compound for PD that is levodopa. For the prediction of activity 
in the different targets of PD, canonical simplified molecular-input 
line-entry system (SMILES) is used which is obtained from PubChem 
website shown in Table 1. These SMILES work as a molecular formula of 
the compound and are directly copied into the PASS software to predict 
the activity.
RESULTS
The selected phytochemical and marketed compound was predicted 
using PASS for nine activities in the PD shown in Table 2. These activities 
are as follows:
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• DA precursor
• Caspase 3 inhibitor
• Anticholinergic
• Free radical scavenger
• Nootropic activity
• Monoamine oxidase (MAO) inhibitor
• DA release stimulant
• N-methyl D-aspartate (NMDA) receptor antagonists
• Antiparkinsonian.
The predicted Pa predicted by PASS is represented in Table 2 and also 
compared with the marketed drug that is levodopa.
DISCUSSION
PD is a progressive neurodegenerative disorder, for which till 
now an effective treatment is not available. Research is going 
on overall the world in this stream. Several compounds have 
passes the preclinical trails but able to come into the clinical trial 
phase, due to lack of informative data. PASS is online software, 
which can be used by anyone after completing free registration. 
This software predicts the biological activity of the chemical 
compound on the bases of chemical structure and interaction 
with the different targets. This software provides an information 
regarding that a particular compound can be beneficial in a 
particular disease. On the basis of which further pharmacological Fig. 1: Available drug therapy of Parkinson disease
Name of compound Canonical SMILES Chemical structure
Levodopa C1=CC(=C (C=C1CC (C(=O) O) N) O) O
Nicotine CN1CCCC1C2=CN=CC=C2
Caffeine CN1C=NC2=C1C(=O) N (C(=O) N2C) C
Resveratrol C1=CC(=CC=C1C=CC2=CC(=CC(=C2) O) O) O
Riluzole C1=CC2=C (C=C1OC (F)(F) F) SC(=N2) N
Table 1: Phytochemicals with canonical SMILES and chemical structure
(Contd...)
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Name of compound Canonical SMILES Chemical structure
Hesperidin CC1C (C (C (C (O1) OCC2C (C (C (C (O2) OC3=CC(=C4C(=O) 
CC (OC4=C3) C5=CC(=C (C=C5) OC) O) O) O) O) O) O) O) O
Baicalein C1=CC=C (C=C1) C2=CC(=O) C3=C (C(=C (C=C3O2) O) O) O
Acetylcholine CC(=O) OC1CC2=CC3=C (C=C2C4C1(C5=C (CN4C) C6=C (C=C5) 
OCO6) C) OCO3
n-Butylidenephthalide CCCC=C1C2=CC=CC=C2C(=O) O1
Stemazole C1=CC(=CC=C1C2=NNC(=S) O2) NC(=S) NN
Celastrol CC1=C (C(=O) C=C2C1=CC=C3C2(CCC4(C3(CCC5(C4CC (CC5)(C) 
C(=O) O) C) C) C) C) O
L-theanine CCNC(=O) CCC (C(=O) O) N
Kaempferol C1=CC(=CC=C1C2=C (C(=O) C3=C (C=C (C=C3O2) O) O) O) O
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testing can be performed to verify the result or the pre-performed 
pharmacological testing can get support from the information 
provided by the software.
In this study, we select certain phytoconstituents which have been 
reported to have beneficial effects in the in vivo and in vitro models 
of PD. One marketed standard drug (levodopa) for PD is also selected 
to compare with the phytoconstituents. All compounds were tested 
for nine activities as shown in Fig. 2. We found that levodopa has 
the highest DA precursor activity when compared to the selected 
phytoconstituents (Fig. 3). Of the phytoconstituents, rosmarinic acid 
has the higher value for DA precursor activity and fisetin has the 
lowest one.
The phytoconstituents which show DA precursor activity follow 
the pattern rosmarinic acid > trehalose > zingerone > L-theanine, 
resveratrol > gastrodin > syringic acid > shogaol > fisetin.
Levodopa was found to have least caspase 3 inhibitory activity, and 
only four phytochemicals show caspase 3 inhibitory activity, Fig. 4. 
L-theanine has the highest value and resveratrol has the least but more 
than levodopa. The value varies such as l-theanine > syringic acid > 
n-butylidenephthalide > resveratrol > levodopa. Similarly, only three 
phytochemicals show anticholinergic activity nicotine > acetylcholine 
> resveratrol, and same was absent in case of levodopa.
In case of anticholinergic activity, only three compounds were 
found to have the anticholinergic activity shown in Fig. 5. Nicotine 
has the highest activity followed by acetylcholine and resveratrol, 
respectively.
Hesperidin was found to have the highest free radical scavenging 
activity shown in Fig. 6. Levodopa also found to have free radical 
scavenging activity, but most of the phytochemicals were found to have 
more value for the same activity, Hesperidin > kaempferol > fisetin > 
Name of compound Canonical SMILES Chemical structure
Gastrodin C1=CC(=CC=C1CO) OC2C (C (C (C (O2) CO) O) O) O
Trehalose C (C1C (C (C (C (O1) OC2C (C (C (C (O2) CO) O) O) O) O) O) O) O
Rosmarinic acid C1=CC(=C (C=C1CC (C(=O) O) OC(=O) C=CC2=CC(=C (C=C2) O) 
O) O) O
Shogaol CCCCCC=CC(=O) CCC1=CC(=C (C=C1) O) OC
Zingerone CC(=O) CCC1=CC(=C (C=C1) O) OC
Syringic acid COC1=CC(=CC(=C1O) OC) C(=O) O
Fisetin C1=CC(=C (C=C1C2=C (C(=O) C3=C (O2) C=C (C=C3) O) O) O) O
SMILES: Simplified molecular-input line-entry system
Table 1: (Continued)
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rosmarinic acid > shogaol > gastrodin > baicalein > zingerone > syringic 
acid > trehalose > resveratrol > carnosic acid > levodopa > l-theanine 
> n-butylidenephthalide > riluzole. Rosmarinic acid and shogaol have 
value almost near to each other.
Again in case of nootropic activity, most of the phytochemicals 
have the higher value than the levodopa, and according to value 
list is like: Nicotine > celastrol > caffeine > zingerone > l-theanine 
> baicalein > resveratrol > shogaol > syringic acid > levodopa > 
acetylcholine > kaempferol. Resveratrol, baicalein, kaempferol, 
and acetylcholine have activity values near to each other shown 
in Fig. 7.
In MAO inhibiting activity, kaempferol has the highest value than 
another phytochemicals and also more than levodopa, kaempferol 
> stemazole > baicalein > resveratrol > levodopa > riluzole > 
caffeine > zingerone > hesperidin > n-butylidenephthalide as 
shown in Fig. 8.
Fig. 2: All activities of all compounds with respect to levodopa
Fig. 3: Dopamine precursor activity of all compounds with respect to levodopa
Fig. 4: Caspase 3 inhibitor activity of all compounds with respect to levodopa
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Levodopa was found to have the highest DA release stimulant activity, 
when compared to the selected phytochemicals shown in Fig. 9. 
Zingerone found to have the highest value among the phytochemicals 
but less than levodopa. Other compounds having DA release activity 
are as follow: Levodopa > zingerone > baicalein > resveratrol > syringic 
acid > shogaol > l-theanine > rosmarinic acid > fisetin > kaempferol > 
nicotine > n-butylidenephthalide > riluzole. Nicotine, kaempferol, and 
n-butylidenephthalide have to value almost near to each other.
In case of NMDA receptor antagonist activity, the phytochemicals does 
not have a good value even levodopa shown in Fig. 10. Resveratrol has the 
highest value, but it is only 0.232 which is not much more than levodopa 
(0.186). The compound which shows the NMDA receptor antagonist 
activity, their values lie almost in the same range or slightly differ from 
each other.
Only two compounds resveratrol and l-theanine have more values 
than levodopa rest are having less than levodopa. Other compounds 
having NMDA receptor antagonist activity are as follow: Resveratrol 
> l-theanine > levodopa > zingerone > syringic acid > baicalein > 
kaempferol > n-butylidenephthalide > rosmarinic acid > shogaol > 
trehalose > nicotine.
Fig. 5: Anticholinergic activity of all compounds with respect to levodopa
Fig. 6: Free radical scavenging activity of all compounds with respect to levodopa
Fig. 7: Nootropic activity of all compounds with respect to levodopa
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Being a standard drug therapy for PD, levodopa does not found to 
have a good antiparkinsonian activity, when compared to certain 
phytochemicals as shown in Fig. 11. Riluzole was found to have 
the highest antiparkinsonian activity among the phytochemicals 
and also more than levodopa. Carnosic acid, l-theanine, syringic 
acid, and n-butylidenephthalide have values near to each other, 
but syringic acid and n-butylidenephthalide have the same activity 
values.
Various phytochemicals are present in plants, but only few were 
explored for their pharmacological activities and rest are unexplored. 
Testing every compound by hit and trial method for pharmacological 
activity is not an easy task as it is tedious and costly. However, with the 
help of PASS, a pathway can be generated to evaluate the phytochemical 
for a particular pharmacological activity. PASS not only provides a 
supportive information for the pre-explored phytochemicals but also 
provides information regarding their hidden potential activities which 
previously not known.
CONCLUSION
From the above study, it can be concluded that PASS provides an 
informative data to support the reported activities of the phytochemicals. 
It can also help the researcher to decide and to prepare a protocol for 
Fig. 8: Monoamine oxidase inhibiting activity of all compounds with respect to levodopa
Fig. 9: Dopamine release stimulant activity of all compounds with respect to levodopa
Fig. 10: N-methyl D-aspartate receptor antagonist activity of all the compounds with respect to levodopa
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testing a new phytochemical for a particular pharmacological action as 
well as to test a pre-reported phytochemical for a new activity.
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